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Abstract
Transforming growth factor-beta1 (TGF-beta1) exerts potent immunosuppressive effects. In
this study, we investigated the potential role of TGF-beta1 produced by hepatocellular carcinoma
(HCC) cell lines in immunosuppression mechanisms. Using the Mv1Lu cell-growth inhibition
assay and an enzyme-linked immunosorbent assay (ELISA), we detected optimal levels of TGF-
beta1 in the culture supernatants conditioned by the HCC cell lines PLC/PRF/5, Hep3B, and
HepG2. To determine the biological activity of TGF-beta1 in the supernatants, we examined the
effects of the culture supernatants on the production of interferon (IFN)-gamma induced during
the culture of peripheral blood mononuclear cells (PBMCs) stimulated with interleukin (IL)-12.
IFN-gamma production of IL-12-stimulated PBMCs in the 1:1 dilution of the acid-activated con-
ditioned medium of PLC/PRF/5, Hep3B, and HepG2 reduced to 14.7 +/- 0.8, 17.3 +/- 9.0, and
35.9 +/- 14.6%, respectively, compared with the value in the culture with control medium (com-
plete culture medium). These results suggest that HCC cells producing TGF-beta1 may reduce the
generation or activation of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, and thus
could enhance their ability to escape immune-mediated surveillance.
KEYWORDS: hepatocellular carcinoma, immunosuppression, transforming growth factor-?1 (TGF-
?1), interleukin-12, interferon-? (IFN-?)
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Transforming growth factor- 1 (TGF- 1)exerts potent immunosuppressive eﬀects. In this study,
we investigated the potential role of TGF- 1 produced by hepatocellular carcinoma(HCC)cell lines in immunosuppression mechanisms. Using the Mv1Lu cell-growth inhibition assay and an enzyme-
linked immunosorbent assay(ELISA), we detected optimal levels of TGF- 1  in the culture super-
natants conditioned by the HCC cell lines PLC/PRF/5, Hep3B, and HepG2. To determine the biological activity of TGF- 1  in the supernatants, we examined the eﬀects of the culture super-
natants on the production of interferon (IFN)- induced during the culture of peripheral blood mononuclear cells (PBMCs) stimulated with interleukin (IL)-12. IFN- production of IL-12-
stimulated PBMCs in the 1:1 dilution of the acid-activated conditioned medium of PLC/PRF/5,
Hep3B, and HepG2 reduced to 14.7±0.8, 17.3±9.0, and 35.9±14.6 , respectively, compared with the value in the culture with control medium(complete culture medium). These results suggest that HCC cells producing TGF- 1 may reduce the generation or activation of cytotoxic T lymphocytes
(CTL)and natural killer(NK)cells, and thus could enhance their ability to escape immune-mediated surveillance.
Key words:hepatocellular carcinoma, immunosuppression, transforming growth factor-β?(TGF-β?), interleukin-
12, interferon-γ(IFN-γ)
I t is suggested that anti-tumor reactivity may be altered in cancer patients. Previously, the secre-
tion of immunosuppressive factors from tumor cells appeared to be one of several immunosuppression mecha-
nisms, by which tumors evolve to escape from the immune responses［1, 2］. Transforming growth factor-
β?(TGF-β?), a member of a family of peptide factors regulating cell growth and diﬀerentiation［3］, has also
 
been shown to exert potent immunosuppressive eﬀects
［4］. The immunosuppressive properties of TGF-β?
have been shown to modulate the immune response by aﬀecting proliferation, the activation state, and diﬀerentiation of natural killer(NK)cells and cytotoxic T cells［5, 6］.
TGF-β?is overexpressed in most common forms of cancer［7-10］. In addition, in patients with hepatocel-
lular carcinoma(HCC), TGF-β?plasma levels have been found to be elevated［11］and expression in the HCC cells to be increased［12-14］. In contrast, in HCC patients, the NK cell activity,which is believed to play an
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important role in host anti-tumor defense mechanisms,
appears to be signiﬁcantly decreased. The reduced activ-
ity have been shown to be associated with the progression of HCC(15, 16). Taken together, it is possible that the TGF-β?produced by HCC cells may exert negative eﬀects on anti-tumor immunity against HCC.
It has recently been reported that tumor cell-derived TGF-β?and interleukin(IL)-10 in conditioned media of pancreatic carcinoma cell lines inhibits both the prolifera-
tion and development of Th1-like responses in peripheral blood mononuclear cells (PBMCs)derived from normal donors［10］. However, the immunosuppressive eﬀects of HCC-derived TGF-β?have not been fully studied.
IL-12, a monocyte/macrophage-derived cytokine, pro-
motes the cytolytic maturation and proliferation of T and NK cells, and the release of interferon (IFN)-γfrom these eﬀector cells［17, 18］. Furthermore, IL-12 has been shown to have potent anti-tumor activity in tumor models, including HCC［19, 20］. Thus, in the present study, the TGF-β?secreted from HCC cell lines was assessed for its inhibitory eﬀects on the production of IFN-γinduced during the culture of PBMCs stimulated by IL-12, to investigate the potential role of HCC-derived TGF-β?in immunosuppression mechanisms.
Materials and Methods
 
Human HCC cell lines PLC/PRF/5［21］, Hep3B［22］, and HepG2［23］were assessed for TGF-β?production.
These HCC cells were grown in Minimal Essential Medium(MEM;Sigma Chemicals Co., St. Louis, MO,
USA)supplemented with 10  heat-inactivated fetal calf serum(FCS), 100 units/ml penicillin, and 100μg/ml streptomycin at 37°C in a humidiﬁed atmosphere of 5 CO?in 95  air.
Peripheral blood mononuclear cells (PBMCs)were iso-
lated by Ficoll-Hypaque (Pharmacia Biotech, Uppsala,
Sweden)centrifugation from the peripheral blood samples,
which were obtained from 5 patients with unresectable huge HCC, or from 7 healthy volunteers. The patients with HCC were diagnosed based on ultrasound sonogra-
phy, abdominal computed tomography, and angiography
(Table 1). Seven healthy volunteers (5 males and 2 females, median age 36, range 33-40)with no known liver disease served as control subjects. Informed consent was obtained from all patients and healthy control sub-
jects.
G
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The expression of TGF-β?messenger ribonucleic acid
(mRNA)in the HCC cell lines PLC/PRF/5, Hep3B,
and HepG2 were assessed by reverse transcription-
polymerase chain reaction (RT-PCR). The PCR was carried out with complementary deoxyribonucleic acid
(cDNA) derived from 2μg of RNA, 1 unit of Taq polymerase(Recombinant Taq DNA polymerase;Takara Shuzo Co., Ohtsu, Japan), and a reaction kit in a ﬁnal volume of 7μl. The PCR conditions included denatura-
tion at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min. Thirty cycles of PCR were performed on each sample, after which the products were separated on 2  agarose gels.
The PCR primers used here for the ampliﬁcation of TGF-β?-, andβ-actin-speciﬁc sequences were as fol-
lows;TGF-β?:5-’GCCCTGGACACCAACTATTGCT-
3’(sense strand)and 5’-AGGCTCCAAATGGGGCAGG-3’
(antisense strand), and β-actin:5’-ATCTG CACCA CACCTTCTACAATGAGCTGCG-3’(sense strand)and 5’-CGTCATACTCCTGCTTGCTGATCCACATCTGC-3’
(antisense strand). The PCR using these primers yielded 161-bp and 838-bp products, respectively.
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Culture supernatants conditioned by HCC cell lines were tested for TGF-β?. HCC cells (1×10?
c )lls/10 m  t of culture medium  d werecul  t ure h for 96 a
 
Mouri et al. Acta Med. Okayama Vol. 56, No. 6 310
 
Table 1  Clinical proﬁles of patients with hepatocellular carcinoma
 
Patients with hepatocellular carcinoma
 
No.of cases  5 Gender(Male/Female) 4/1 Age(years) 50(48-76)?
HBV/HCV  3/2 Liver disease(CH/LC) 4/1 Alb(3.9-4.9 mg/dl) 3.5(2.79-3.96)
AST(11-32 IU/l) 86(24-130)
ALT(6-39 IU/l) 42(17-87)
AFP(＜7.0 IU/ml) 4.9 (1.3-57135)
PIVKA-II(＜28 mAU/ml) 629 (17-57500)
KICG  0.132(0.085-0.198)
Size of main tumor(cm) 120(27-145)
?,Values are expressed as Median(Minimum-Maximum).AFP,alpha-
fetoprotein;Alb, albumine;ALT, alanine aminotransferase;AST,
aspartate aminotransferase;CH,chronic hepatitis;HBV,hepatitis B virus;HCV, hepatitis C virus;LC, liver cirrhosis;PIVKA-II, protein induced by vitamin K absence or antagonist-II.
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37°C in a humidiﬁed atmosphere of 5 CO?in 95  air.
After the incubation, the culture supernatant conditioned by HCC cells was collected and used as conditioned medium for subsequent experiments.
TGF-β?is secreted as a latent form that can be converted into a biological active form by exposure to extremes of pH, heat or by treatment with proteases
［24］. For subsequent experiments, conditioned medium samples were treated with 0.12 N HCl for 30 min on ice and neutralized with 0.1 M HEPES buﬀer containing 0.144 M NaOH (acid-treatment)［25］. The acid-treated conditioned medium samples of the HCC cells were assessed for TGF-β?by a biological growth-inhibition assay using Mv1Lu mink lung cells［26］, the growth of which is inhibited by TGF-β?in a dose-dependent manner, and by a speciﬁc enzyme-linked immunosorbent assay(ELISA, Morinaga Institute of Biological Science,
Yokohama, Japan).
To determine the TGF-β?levels in the culture medium of HCC cells by the Mv1Lu cell-growth inhibi-
tion assay, we incubated 5×10?cells of Mv1Lu mink lung cells with the acid-activated culture supernatant conditioned by the HCC cells diluted in the culture medium, or with the culture medium containing the recombinant human TGF-β?(Wako Pure Chemical Industries, Ltd., Osaka, Japan)ranging from 0.1 to 10 ng/ml in 96-well ﬂat-bottom microtiter plates. The plates were incubated at 37°C with 5 CO?for 72 h. After the 72-h incubation, the cell-growth in each well was deter-
mined in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay. Standard growth-
inhibition curves were obtained by plotting the cell growth of the treated cells versus the recombinant human TGF-
β?concentrations. TGF-β?levels in the culture medium samples were obtained by determining the concentrations from the standard curve.
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To test whether the inhibitory eﬀects of TGF-β?involve a down-regulation of IFN-γ
production from IL-12-stimulated PBMCs, we examined IFN-γproduction in the presence of recombinant human TGF-β?added at the initiation of the PBMCs stimulation with IL-12. PBMCs(5×10?cells/100μl/well)derived from 5 patients with HCC or from 7 normal donors were cultured with IL-12 (10 ng/ml) (R & D Systems,
Minneapolis, MN, USA)in the presence or absence of recombinant human TGF-β?in 96-well ﬂat-bottom mi-
crotiter plates. The plates were incubated at 37°C in a 5 CO?atmosphere for 48-h, and the supernatants were collected and assessed for IFN-γ production using speciﬁc ELISA(BioSource International, CA, USA).
n
 
To show the biologic activity of TGF-β?in the supernatants conditioned by HCC cell lines, we examined the eﬀects of the culture supernatants on the IFN-γproduction induced in the culture of IL-12-stimulated PBMCs. Acid-activated con-
ditioned supernatant samples diluted in the complete culture medium were added to the culture of PBMCs obtained from HCC patients in the presence of IL-12(10 ng/ml) in 96-well ﬂat-bottom microtiter plates. The supernatants were collected after the 48-h incubation and tested for IFN-γ. Results are presented as percentages of the control IFN-γproduction(culture medium).
To conﬁrm the speciﬁcity of the inhibition of IFN-γ
production from IL-12-stimulated PBMCs, the super-
natant samples conditioned by HCC cells were preabsor-
bed with anti-TGF-β?monoclonal antibodies(Wako Pure Chemical Industries, Ltd., Osaka, Japan)-conjugated Protein A sepharose(Sigma Chemicals Co. St. Louis,
MO, USA). Normal (nonimmune)mouse monoclonal antibody was used as a negative control. Then, in a 1:1 dilution of preabsorbed conditioned supernatant, PBMCs were cultured with IL-12. IFN-γ productio
 
e
 
in the culture with preabsorbed supernatants was compared with that in the culture with nonabsorbed supernatants.
The changes in each of the variables were assessed by Wilcoxon’s sign-rank test or the Student’s t-test. Nonpaired data were compared by the analysis of the Mann-Whitney U-test. A P value less than 0.05 was consider
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tistically signiﬁcant.
Results
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1 . The human HCC cell lines PLC/PRF/5, Hep3B, and HepG2 were assessed for TGF-β?production. To conﬁrm the production of TGF-β?, HCC cells were tested for the expr
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supernatants conditioned for 4 days by HCC cell lines
(Table 2). In addition, using an ELISA that recognized the biologically active form of TGF-β?, we detect the optimal level of TGF-β?(2.3-7.3 ng/ml)in the culture supernatants conditioned by the three HCC cell lines
(Table 2). These ﬁndings suggest that the HCC cell lines produced and secreted signiﬁcant quantities of TGF-β?
into the culture medium.
9
 
1
/
We examined the eﬀects of recombinant human TGF-β?on IFN-γproduction by IL-12-stimulated PBMCs, which were obtained from 5 HCC patients or from 7 normal donors. The mean IFN-γ production in the culture of IL-12-stimulated
 
PBMCs derived from the HCC patients was 2043±630 pg/ml (median 1766 pg/ml, range 1511-3022 pg/ml),
which was not signiﬁcantly diﬀerent from that of the normal donors (1597±400 pg/ml, median 1547 pg/ml,
range 1170-2131 pg/ml)(P＝0.223). The results illus-
trated in Fig. 2 show that TGF-β?used at various concentrations from 0.1 to 10 ng/ml inhibited the produc-
tion of IFN-γby IL-12-stimulated PBMCs in a dose-
dependent manner. The mean IFN-γ production by IL-12-stimulated PBMCs in the presence of 0.1, 1.0, or 10 ng/ml of recombinant human TGF-β?was 1572±
578, 947±480, and 5
 
n
 
6±290 pg
 
C
 
ml in the HCC patients, and 1277±512, 607±211, and 421±219 pg/ml in the normal donors, respectively, suggesting that TGF-β?inhibited the IFN-γproduction by IL-12-
stimulated PBMCs derived from patie ts with H C in a manner similar to those of healthy subjects.
h n f We  t ou  t d a
 
Table 2  TGF-β?concentration in the culture supernatant of HCC cell lines
 
HCC cell line  Bioassay(ng/ml) ELISA(ng/ml)
PLC/PRF/5  13.6  2.3 Hep3B  13.6  7.3 HepG2  13.5  3.4
 
ELISA, enzyme-linked immunosorbent assay.
Fig.1  Analysis of transforming growth factor(TGF)-β?mRNA by reverse transcription-polymerase chain reaction(RT-PCR). Total RNA was prepared from human the hepatocellular carcinoma cell lines PLC/PRF/5(lane 2 and 3), Hep3B(lane 4 and 5), and HepG2(lane 6 and 7). Total RNA was analyzed by RT-PCR for the expression of TGF-β?mRNA(lane 2, 4, and 6;161 bp)andβ-actin mRNA(lane 3,
5, and 7;838 bp). Lane 1, molecular size-marker;lane 8, positive control cDNA fragment.
Fig.2  Suppressive eﬀects of transforming growth factor(TGF)-β?
on interferon (IFN)-γproduction in the culture of peripheral blood mononuclear cells (PBMCs) stimulated with interleukin (IL)-12.
PBMCs (5×10?cells/100μl/well)derived from 7 healthy subjects
( )and from 5 patients with HCC( )were cultured with IL-12
(10 ng/ml)in the presence or absence of human recombinant TGF-β?
added at the beginning of the culture period at the indicated concen-
trations. Culture supernatants were collected after the culture for 48-h, and tested for the IFN-γ production. IFN-γ production is presented as the mean±SD of the 7 normal subjects and the 5 HCC patients, respectively. Asterisks indicate statistically signiﬁcant diﬀerences(P＜0.05 in Wilcoxon’s sign-rank test)between data sets when compared to controls in the absence of TGF-β?in healthy subjects (?)and in HCC patients ( ), respectively.
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HCC cells secreted TGF-β?into the culture medium in a biologically inert form that was unmasked by the acid-
treatment. We next investigated whether TGF-β?in the culture supernatants was eﬀective in suppressing the IFN-γproduction in the culture of PBMCs stimulated with IL-12. As shown in Fig. 3, IFN-γproduction of IL-12-stimulated PBMCs in the 1:1 dilution of the acid-activated conditioned medium of PLC/PRF/5,
Hep3B, and HepG2 was reduced to 14.7±0.8, 17.3±
9.0, and 35.9±14.6 , respectively, compared with the value in the culture with control medium(2370±880 pg/
ml, complete culture medium). IFN-γ production of IL-12-stimulated PBMCs in the 1:4 dilution of the conditioned medium of PLC/PRF/5, Hep3B, and HepG2 were 54.1±48.6, 53.3±14.6, and 46.0±17.9
, respectively. These results suggest that the acid-
activated supernatants suppressed in a dose-dependent manner the IFN-γproduction that was induced in the culture of PBMCs stimulated with IL-12.
To conﬁrm that the biological activities of the super-
natants were indeed due to TGF-β?, the supernatants were preabsorbed with anti-TGF-β? monoclonal antibody-conjugated Protein A-Sepharose. As shown in Fig. 3, the inhibitory eﬀects of the 1:1 dilution of
 
conditioned supernatants on the IFN-γproduction from IL-12-stimulated PBMCs were completely overcomed by the preabsorption(114.6±12.6, 125.1±34.0, 132.5±
27.0 , respectively), indicating that the suppressive eﬀects on IFN-γproduction were due to the TGF-β?in the supernatants conditioned by HCC cells.
Discussion
 
Certain tumors have been shown to produce large amounts of TGF-β?［7-10］. TGF-β?is also produced from hepatocellular carcinoma cells［12-14］. In the present study, we determined that TGF-β?is present in culture supernatants conditioned with the human HCC cell lines PLC/PRF/5, Hep3B, and HepG2 in a biologically inert form that can be unmasked by acid treatment. In addition, the expressions of TGF-β?mRNA were detect-
ed in these HCC cell lines. These results suggest that the HCC cell lines continue to synthesize TGF-β?in a latent but potentially activated form.
TGF-β?is a cytokine involved in the regulation of cell growth and diﬀerentiation［4］. It has also been shown to modulate immune responses by aﬀecting the proliferation,
activation, and diﬀerentiation of immune cells within the
 
Fig.3  Eﬀects of the culture supernatants conditioned by hepatocellular carcinoma(HCC)cell lines PLC/PRF/5, Hep3B, and HepG2 on the production of interferon (IFN)-γinduced in the culture of peripheral blood mononuclear cells (PBMCs)stimulated with interleukin (IL)-12.
PBMCs(5×10?cells/100μl/well)derived from 3 HCC patients were cultured with IL-12(10 ng/ml)in(A)a 1:1 dilution of the conditioned supernatant;(B)a 1:4 dilution of the conditioned supernatants;(C)a 1:1 dilution of the conditioned supernatants, which were preabsorbed with anti-TGF-β?monoclonal antibodies conjugated Protein A-Sepharose;(D)the culture medium containing human recombinant TGF-β?(5 ng/ml);or(E)the culture medium containing human recombinant TGF-β?, which was preabsorbed with anti-TGF-β?monoclonal antibody-
conjugated Protein A-Sepharose. Culture supernatants were collected after the incubation for 48-h and tested for IFN-γ. Results are presented as percentages of the control IFN-γproduction(culture medium). Values are presented as the means±SD of the 3 HCC patients. Asterisks indicate a statistically signiﬁcant diﬀerence(P＜0.05 in Student’s t-test)between 2 mean values.
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framework of the immune-cell network［5, 6］. There-
fore, it is reasonable to consider that the TGF-β?
produced by HCC cells could suppress the immune cells surrounding HCC cells, subsequently enhancing the ability of HCC to escape immune surveillance. However,
with regard to the TGF-β?produced by HCC cells, there have been few studies of the immunosuppressive eﬀects on the cell-mediated immune response.
The ﬁndings of the present study clearly show that recombinant human TGF-β?inhibits the IFN-γproduc-
tion induced in the culture of PBMCs stimulated with IL-12, as reported previously［27-29］. These results suggest that TGF-β?inhibits the responsiveness of T and NK cells to IL-12. IL-12 acts on T and NK cells by inducing the proliferation and production of cytokines,
and by enhancing the activity of CTL and NK cells［17,
18］. Therefore, the TGF-β?-dependent inhibition of biological activities of IL-12 may contribute to the inhibi-
tion of cell-mediated immune responses and the subse-
quent suppression of anti-tumor immunities. It has recently been reported that TGF-β?antagonizes the ability of IL-12 to stimulate the IFN-γproduction of lymphocytes by inhibiting IL-12-inducing signaling mole-
cules［27］or by interfering with the normal expression of IL-12 receptors (IL-12R)［28］.
The present results demonstrate that the TGF-β?
secreted by HCC cell lines into a culture medium also inhibits the IFN-γ production by IL-12-stimulated PBMCs obtained from HCC patients. These ﬁndings indicate that TGF-β?-producing HCC cells may reduce the generation or activation of CTL and NK cells, and thus could enhance their ability to escape immun-mediated surveillance. Bellone G et al., also have reported that TGF-β?and IL-10 secreted into the conditioned medium of pancreatic carcinoma cell lines signiﬁcantly reduced the production of IFN-γby PBMCs obtained from three normal donors upon activation by anti-CD3 antibody.
From these results, they suggested that production of either TGF-β?or a combination of IL-10 and TGF-β?
by pancreatic carcinoma cells contributes to the inhibition of Th1-like responses in naı?ve PBMCs.
On the other hand, the escape from immune destruc-
tion, which is partially acquired by secreting immunosup-
pressive factors, might be circumvented by inhibiting the expression of these factors. Fakhrai et al.［29］have recently reported that subcutaneous immunization of glioma-bearing rats with 9L glioma cells genetically modiﬁed to inhibit TGF-β?expression with an antisense
 
plasmid vector results in a signiﬁcantly higher number of animals surviving for 12 weeks compared with immuniza-
tions with control vector-modiﬁed 9L cells. They also found that in vitro tumor cytotoxicity assays with lymphnode eﬀector cells results in a 3-to 4 fold increase in lytic activity in animals immunized with TGF-β?
antisense-modiﬁed tumor cells compared with immuniza-
tion with control vector. These results suggest that inhibition of TGF-β?expression signiﬁcantly enhances tumor-cell immunogenecity and supports the view that immunization with tumor cells genetically modiﬁed to suppress TGF-β?may be eﬃcacious against established tumors expressing TGF-β?.
HCC is liable to occur even after the curative therapy.
Therefore, the development of new therapies such as immunotherapy is essential to prevent recurrence. The present ﬁndings may have important implications for the development of immunotherapies for HCC. Strategies to inhibit the expression of TGF-β?in HCC cells may provide clues to develop active immunotherapies for HCC.
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